Pembrolizumab is a humanized monoclonal antibody targeting PD‐1 that exerts antitumor activity in advanced NSCLC; its therapeutic effect is closely related to PD‐L1 expression in cancer cells, and PD‐L1 protein expression has been suggested to be a predictive biomarker of the response to immunotherapy.31 The gene discussed is CD274; the disease is cancer.